Dato-DXd did not improve survival in the overall population with non-small cell lung cancer but did boost outcomes in patients with non-squamous disease. Dato-DXd (datopotamab deruxtecan) did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback